# Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

> **NCT03858166** · PHASE4 · TERMINATED · sponsor: **Shandong University** · enrollment: 68 (actual)

## Conditions studied

- Adjuvant Chemotherapy
- Ovarian Neoplasms
- Ovarian Cancer

## Interventions

- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT03858166
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Sponsor Termination
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03858166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03858166, "Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03858166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*